Due to the divergent national decisions taken by Member States concerning the authorisation of Zyrtec, a number of divergences exist in the product information and a referral was therefore triggered by the European Commission Article 30 of Directive 2001/ 83/ EC as amended in order to harmonise the divergent Product Information texts across the EU.